Combined treatment in advanced stages (IIIb-IV) of non-small cell lung cancer

European Review for Medical and Pharmacological Sciences

Volumn 6, Issue 2, 2002, Pages 49-54

  Mariotta, S ^a,b   Sposato, B ^a,b   Li Bianchi, E ^b   Fiorucci, F ^b   Ricci, A ^a,b   Carbone, F ^a,b   Crescenzi, M ^c   Schmid, G ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Centro Trasfusionale Universitario   (Italy)

^c Servizio Radioterapia   (Italy)

Author keywords

Cisplatin; Combined therapy; Epirubicin; Non small cell lung cancer; Radiotherapy; Surgery

Indexed keywords

AMINOTRANSFERASE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LIVER ENZYME; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; ECG ABNORMALITY; FEMALE; FEVER; FIBEROPTIC BRONCHOSCOPY; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PHLEBITIS; RADIATION DOSE; REVIEW; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 0036524509     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. FAULDS D. Current options in the treatment of non-small cell lung cancer. Drugs 1992; 44: 46-59.
2. NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP. Chemotherapy in non-small lung cancer: a meta-analysis using update data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
3. SCHILLER JH, HARRINGTON D, BELANI CP, LANGER C, SANDLER A, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
4. SCHILLER JH. Current standards of care in small-cell lung and non-small cell lung cancer. Oncology 2001; 61: 3-13.
5. PISTERS KMW. Adjuvant and Neo-adjuvant therapy for early stage non-small cell lung cancer. Semin Oncol 2001; 28 (Suppl 14): 23-28.
6. NOVELLO S, LE CHEVALIER T. Is there a standard strategy in the management of locally advanced non-small cell lung cancer? Lung Cancer 2001; 34: S9-S14.
7. JASSEM J. Combined modality treatment with chemotherapy and radiation in locally advanced non-small lung cancer. Lung Cancer 2001; 34: S181-S183.
8. GRIDELLI C, IACOBELLI S, MARTINO T, NATOLI C, FERRANTE G, et al. Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small lung cancer: a pilot study. Tumori 1992; 78: 377-379.
9. NUMICO G, RUSSI E, MERLANO M. Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy? Lung Cancer 2001; 32: 213-226.
10. PLOWER GL, FAULDS D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993; 45: 788-856.
11. MARTONI A, MELOTTI B, GUARALDI M, PANNUTI F. Activity of high-dose epirubicin in advanced non-small-cell lung cancer (NSCLC). Eur J Cancer 1991; 27: 1231-1234.
12. FELD R, WIERZBICKI R, WALDE PL, SHEPHERD FA, EVANS WK, et al. Phase I-II study of high-dose epirubicin in advanced non-small lung cancer. J Clin Oncol 1992; 10: 297-303.
13. WILS J, UTAMA I, SALA L, SMEETS J, RIVA A. Phase II study of high-dose epirubicin in non-small-cell lung cancer. Eur J Cancer 1990; 26: 1140-1141.
14. SMIT EF, BERENDSEN HH, PIERS DA, SMEETS J, RIVA A, POSTMUS PE. A phase II study of high-dose epirubicin in unresectable non-small-cell lung cancer. Br J Cancer 1992; 65: 405-408.
15. MARTONI A, GUARALDI M, CASADIO M, BUSUTTI L, PANNUTI F. A phase II study of high-dose epirubicin plus cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 1992; 3: 864-866.
16. VAN PUTTEN JMG, EPPINGA P, ERJAVEC Z, DE LEEDE G, NABERS J, et al. Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study. Br J Cancer 2000; 82: 806-811.
17. CERESOLI GL, DELL'ORO S, PASSONI P, VILLA E. Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic non-small-cell lung carcinoma. Cancer 2000; 89: 89-96.
18. MILLER AB, HOOGSTRATEN B, STAQUET M, WINKLER A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
19. BONOMI P, KIM K, FAIRCLOUGH D, BONOMI P, KIM K, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Coperative Oncology Group trial. J Clin Oncol 2000; 18: 623-631.
20. CARDENAL F, LOPEZ CABRERIZO MP, ANTON A, ALBEROLA V, MASSUTI B, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17: 12-18.
21. MARTONI A, GIOVANNINI M, TOMASI L, CAMAGGI CM, BELLANOVA B, et al. A phase II clinical trial of 4′-epidoxorubicin in advanced solid tumors. Cancer Chemoter Pharmacol 1984; 12: 179-182.
22. JOSS RA, HANSEN HH, HANSEN M, RENARD J, ROZENCWEIG M. Phase II trial of epirubicin in advanced squamous adeno- and large-cell carcinoma of the lung. Eur J Cancer Clin Oncol 1984; 20: 495-499.
23. MARTONI A, GUARALDI M, PIANA E, STROCCHI E, PETRALIA A, et al. Multicenter randomized clinical trial on high-dose epirubicin plus cisplatin versus vinorelbine plus cisplatin in advanced non-small cell lung cancer. Lung Cancer 1998; 22: 31-38.
24. CLERICI M, DE MARINIS F, PIAZZA E, FRONTINI L, TUCCI E, et al. Phase II of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer. Tumori 1998; 84: 669-672.
25. QUANTIN X, RIVIERE A, DAURES JP, OLIVER P, COMTE-BARDONNET M, et al. Phase I-II study of high-dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer. Am J Clin Oncol 2000; 23: 192-196.
26. HUISMAN C, BIESMA B, POSTMUS PE, GIACCONE G, SCHRAMEL FM, SMIT EF. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. Br J Cancer 2001; 85: 1456-1461.
27. WOZNIAK AJ, CROWLEY JJ, BALCERZAK SP, WEISS GR, SPIRIDONIDIS CH, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459-2465.
28. FILIPPAZZI V, CATTANEO MT, RHO B, FRONTINI L, D'ADDA D, et al. Cisplatin plus epirubicin and etoposide followed by irradiation plus Ionidamide in stage III nonsmall cell lung cancer. Oncology 1993; 50: 10-13.
29. FURUSE K, FUKUOKA M, KAWAHARA M, NISHIKAWA H, TAKADA Y, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.